La vendita allo scoperto per InfuSystems Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di InfuSystems Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

InfuSystems Holdings (AMEX:INFU) Azioni, Report sulle vendite allo scoperto

InfuSystems Holdings

InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.

InfuSystems Holdings Inc

INFUSION BRANDS INTL INC by Infusion Brands International, Inc.

Infusion Brands International Inc

Full Year 2024 Guidance
InfuSystem is reaffirming its annual guidance for the full year 2024 with net revenue growth estimated to be in the high-single-digit range and forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 17.8% in 2023.

Earnings

News

Guidance

INFU

InfuSystem Reiterates Its 2024 Guidance Of Net Revenue Growth Expected To Be In The High-Single-Digit Range And Adjusted EBITDA To Be In The High-Teens

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $35.320 million which beat the analyst consensus estimate of $34.483 million by 2.43 percent. This is a 10.69 percent increase over sales of $31.909 million the same period last year.

Earnings Beats

InfuSystems Holdings Q3 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $35.320M Beat $34.483M Estimate

B. Riley Securities initiates coverage on InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) with a Buy rating and announces Price Target of $13.

Price Target

Initiation

Analyst Ratings

B. Riley Securities Initiates Coverage On InfuSystems Holdings with Buy Rating, Announces Price Target of $13

Health Care

Contracts

General

InfuSystem And Its Joint Venture Partner Sanara Medtech Executed An Exclusive United States Distribution Agreement With ChemoMouthpiece, Sanara Invested $5M For A 6.6% Ownership Position In ChemoMouthpiece

Full Year 2024&nbsp;Guidance
InfuSystem is reaffirming its annual&nbsp;guidance&nbsp;for the full year 2024 with net revenue growth estimated to be in the high-single-digit range and forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company&#39;s margin of&nbsp;17.8%&nbsp;in 2023.

InfuSystem Reaffirms Its 2024 Guidance Of Net Revenue Growth Expeted To Be In The High-Single-Digit Range And Adjusted EBITDA To Be In The High-Teens

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.04 by 25 percent. This is a 50 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $33.698 million which beat the analyst consensus estimate of $33.252 million by 1.34 percent. This is a 6.19 percent increase over sales of $31.735 million the same period last year.

Earnings Misses

InfuSystems Holdings Q2 2024 GAAP EPS $0.03 Misses $0.04 Estimate, Sales $33.698M Beat $33.252M Estimate

InfuSystem Inks Three-Year Distribution Deal With Smith+Nephew For Its Negative Pressure Wound Therapy System And Supplies

A substantial acquisition of company stock options by Scott Shuda, Board Member at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) was reported on May 21, based on a new SEC filing.
What Happened: In a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828024024589//Archives/edgar/data/1337013/000162828024024589/0001628280-24-024589-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Shuda, Board Member at InfuSystems Holdings, acquired stock options for 35,685 shares of INFU. These options provide Shuda with the right to purchase the company's stock at $6.34 per share.
InfuSystems Holdings shares are currently trading up by 0.6%, with a current price of $6.67 as of Wednesday morning. This brings the total value of Shuda's 35,685 shares to $11,776.
<h3>About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>InfuSystems Holdings's Financial Performance</h3>
Revenue Growth: InfuSystems Holdings displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 5.35%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 51.49%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS reflects a decline, falling below the industry average with a current EPS of -0.05.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.67, caution is advised due to increased financial risk.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: InfuSystems Holdings's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 663.0.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.13 is above industry norms, reflecting an elevated valuation for InfuSystems Holdings's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 11.31 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Scott Shuda Makes A Tactical Move: Adds InfuSystems Holdings Stock Options To Portfolio

Paul A. Gendron, Director at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>), reported acquisition of company stock options on May 21, according to a new SEC filing.
What Happened: Uncovered in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828024024587//Archives/edgar/data/1337013/000162828024024587/0001628280-24-024587-index.htm">U.S. Securities and Exchange Commission</a>, Gendron, Director at InfuSystems Holdings, executed an insider options move. This move consisted of acquiring stock options for 35,685 shares of INFU, granting Gendron the right to purchase the company's stock at an exercise price of $6.34 per share.
InfuSystems Holdings shares are currently trading up by 0.6%, with a current price of $6.67 as of Wednesday morning. This brings the total value of Gendron's 35,685 shares to $11,776.
<h3>Get to Know InfuSystems Holdings Better</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>Breaking Down InfuSystems Holdings's Financial Performance</h3>
Revenue Growth: Over the 3 months period, InfuSystems Holdings showcased positive performance, achieving a revenue growth rate of 5.35% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 51.49%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.05.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.67, InfuSystems Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: InfuSystems Holdings's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 663.0.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 1.13, InfuSystems Holdings's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): InfuSystems Holdings's EV/EBITDA ratio, surpassing industry averages at 11.31, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Paul A. Gendron At InfuSystems Holdings Acquires Stock Options

A substantial acquisition of company stock options by Ralph F. Boyd, Jr., Director at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) was reported on May 21, based on a new SEC filing.
What Happened: In a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828024024609//Archives/edgar/data/1337013/000162828024024609/0001628280-24-024609-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Jr., Director at InfuSystems Holdings, acquired stock options for 35,685 shares of INFU. These options provide Jr. with the right to purchase the company's stock at $6.34 per share.
Currently, InfuSystems Holdings shares are trading up 0.6%, priced at $6.67 during Wednesday's morning. This values Jr.'s 35,685 shares at $11,776.
<h3>All You Need to Know About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>Understanding the Numbers: InfuSystems Holdings's Finances</h3>
Revenue Growth: InfuSystems Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.35%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 51.49%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.05.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.67, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 663.0 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 1.13 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): InfuSystems Holdings's EV/EBITDA ratio, surpassing industry averages at 11.31, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Move: Ralph F. Boyd, Jr. Enhances Portfolio With InfuSystems Holdings Stock Options

WIIM

InfuSystems shares are trading higher after the company announced a $20 million stock buyback program.

Buybacks

InfuSystem Announces $20M Stock Buyback Program

On May 16, it was revealed in an SEC filing that Scott Shuda, Director at InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001337013/000162828024023875//Archives/edgar/data/1337013/000162828024023875/0001628280-24-023875-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Shuda, Director at InfuSystems Holdings, a company in the Health Care sector, just exercised stock options worth 35,000 shares of INFU stock with an exercise price of $4.7.
Currently, InfuSystems Holdings shares are trading up 2.84%, priced at $6.52 during Friday's morning. This values Shuda's 35,000 shares at $63,699.
<h3>All You Need to Know About InfuSystems Holdings</h3>
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
<h3>Financial Milestones: InfuSystems Holdings's Journey</h3>
Revenue Growth: Over the 3 months period, InfuSystems Holdings showcased positive performance, achieving a revenue growth rate of 5.35% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a high gross margin of 51.49%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): InfuSystems Holdings's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.05.
</li>
</ul>
Debt Management: InfuSystems Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 0.67. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 634.0 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.08 is above industry norms, reflecting an elevated valuation for InfuSystems Holdings's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): InfuSystems Holdings's EV/EBITDA ratio of 10.91 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337013">Check Out The Full List Of InfuSystems Holdings's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Sale: Scott Shuda Decides To Exercise Options Worth $63K At InfuSystems Holdings

InfuSystem Reaffirms FY24 Guidance With Net Revenue Growth Estimated To Be In The High-Single-Digit Range

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.02 by 350 percent. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $31.995 million which missed the analyst consensus estimate of $32.000 million by 0.02 percent. This is a 5.35 percent increase over sales of $30.370 million the same period last year.

InfuSystems Holdings Q1 2024 GAAP EPS $(0.05) Misses $0.02 Estimate, Sales $31.995M Miss $32.000M Estimate

The company intends to regain compliance with the Exchange&#39;s continued listing standards. There can be no assurance that the company will ultimately regain compliance with all applicable Exchange listing standards.

InfuSystem Gets Notice From NYSE American Regarding Late Filing Of Annual Report On Form 10-K

InfuSystems Holdings Sees FY24 Net Revenue Growth In The High-Single-Digit Range and Adjusted EBITDA Margin In The High-Teens

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly sales of $31.77 million which beat the analyst consensus estimate of $30.00 million by 5.90 percent. This is a 10.20 percent increase over sales of $28.83 million the same period last year.

InfuSystems Holdings Q4 Sales $31.77M Beat $30.00M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) is projected to report earnings for its fourth quarter.
&bull; ImmunoPrecise Antibodies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) is likely to report quarterly loss at $0.07 per share on revenue of $4.50 million.
&bull; G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is projected to report quarterly earnings at $0.67 per share on revenue of $817.48 million.
&bull; Dick&#39;s Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is estimated to report quarterly earnings at $3.35 per share on revenue of $3.80 billion.
&bull; Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is likely to report quarterly loss at $0.03 per share on revenue of $5.80 million.
&bull; Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is likely to report quarterly earnings at $0.34 per share on revenue of $405.61 million.
&bull; Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is expected to report quarterly earnings at $0.49 per share on revenue of $455.09 million.
&bull; Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $331.79 million.
&bull; Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is expected to report quarterly loss at $0.04 per share on revenue of $55.39 million.
&bull; Kandi Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNDI#NASDAQ">KNDI</a>) is projected to report earnings for its fourth quarter.
&bull; Benson Hill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NYSE">BHIL</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $87.30 million.
&bull; KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $2.63 billion.
&bull; Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is expected to report quarterly earnings at $1.75 per share on revenue of $9.78 billion.
&bull; Hudson Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $38.02 million.
&bull; InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $30.00 million.
&bull; HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) is likely to report earnings for its fourth quarter.
&bull; Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) is estimated to report earnings for its Fiscal Year 2023.
&bull; Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $23.60 million.
&bull; Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) is likely to report earnings for its fourth quarter.
&bull; Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is projected to report quarterly earnings at $1.32 per share on revenue of $150.45 million.
&bull; Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is projected to report quarterly loss at $0.05 per share on revenue of $6.85 million.
&bull; Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is expected to report quarterly loss at $0.36 per share on revenue of $142.31 million.
&bull; Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) is expected to report quarterly loss at $1.79 per share on revenue of $55.81 million.
&bull; UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) is estimated to report quarterly loss at $0.68 per share on revenue of $22.57 million.
&bull; Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) is projected to report quarterly loss at $0.05 per share on revenue of $47.05 million.
&bull; RumbleON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $339.48 million.
&bull; Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $7.00 million.
&bull; Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) is estimated to report quarterly loss at $0.25 per share on revenue of $360 thousand.
&bull; United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is projected to report earnings for its first quarter.
&bull; BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is likely to report earnings for its fourth quarter.
&bull; Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $166.15 million.
&bull; Mondee Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOND#NASDAQ">MOND</a>) is likely to report quarterly loss at $0.12 per share on revenue of $55.00 million.
&bull; GoHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOCO#NASDAQ">GOCO</a>) is likely to report quarterly earnings at $2.72 per share on revenue of $363.88 million.
&bull; SecureWorks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWX#NASDAQ">SCWX</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $87.18 million.
&bull; Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) is projected to report quarterly loss at $0.02 per share on revenue of $467.40 million.
&bull; PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) is expected to report quarterly loss at $0.47 per share on revenue of $2.47 million.
&bull; Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $1.69 billion.
&bull; CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $58.33 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) is expected to report quarterly loss at $0.09 per share on revenue of $36.93 million.
&bull; Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $56.87 million.
&bull; Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $216.46 million.
&bull; Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is likely to report quarterly earnings at $7.53 per share on revenue of $3.53 billion.
&bull; Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) is projected to report quarterly loss at $1.41 per share on revenue of $38.09 million.
&bull; Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is expected to report quarterly loss at $0.13 per share on revenue of $3.22 million.
&bull; Smartsheet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $255.38 million.
&bull; Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is expected to report quarterly loss at $0.26 per share on revenue of $93.53 million.
&bull; Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) is projected to report quarterly earnings at $0.17 per share on revenue of $191.43 million.
&bull; Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) is projected to report earnings for its third quarter.
&bull; Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) is projected to report earnings for its fourth quarter.
&bull; American Vanguard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $172.90 million.
&bull; The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $98.04 million.
&bull; Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is likely to report earnings for its fourth quarter.
&bull; Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) is likely to report quarterly loss at $0.14 per share on revenue of $1.25 million.
&bull; Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) is likely to report quarterly loss at $0.50 per share on revenue of $1.63 million.
&bull; Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $12.75 million.
&bull; Kopin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) is projected to report quarterly loss at $0.02 per share on revenue of $9.03 million.
&bull; Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) is projected to report earnings for its fourth quarter.
&bull; Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $275.87 million.
&bull; Tilly&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is projected to report quarterly loss at $0.22 per share on revenue of $171.65 million.
&bull; CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) is projected to report quarterly loss at $0.14 per share on revenue of $9.28 million.
&bull; Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $125.84 million.
&bull; Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is projected to report quarterly loss at $0.45 per share on revenue of $20 thousand.
&bull; Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) is expected to report earnings for its fourth quarter.
&bull; Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) is expected to report quarterly loss at $0.12 per share on revenue of $59.72 million.
&bull; Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is estimated to report quarterly loss at $0.32 per share on revenue of $80.97 million.
&bull; Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $124.61 million.
&bull; Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $95.48 million.
&bull; Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) is estimated to report earnings for its fourth quarter.
&bull; Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) is likely to report quarterly loss at $0.03 per share on revenue of $256.27 million.
&bull; Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $89.55 million.
&bull; Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is expected to report quarterly loss at $0.04 per share on revenue of $7.70 million.
&bull; EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $172.41 million.
&bull; Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is expected to report quarterly loss at $0.20 per share on revenue of $3.62 million.
&bull; Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $8.00 million.
&bull; Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $483.69 million.
&bull; Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $291.55 million.
&bull; Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is likely to report earnings for its fourth quarter.
&bull; aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFE#NASDAQ">LIFE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $50 thousand.
&bull; Clipper Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLPR#NYSE">CLPR</a>) is projected to report earnings for its fourth quarter.
&bull; Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is likely to report quarterly earnings at $4.38 per share on revenue of $5.14 billion.
&bull; Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $15.35 million.
&bull; NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) is projected to report quarterly loss at $0.14 per share on revenue of $8.94 million.
&bull; Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) is expected to report quarterly loss at $0.01 per share on revenue of $43.93 million.
&bull; Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) is likely to report earnings for its Fiscal Year 2023.
&bull; FutureFuel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FF#NYSE">FF</a>) is likely to report earnings for its fourth quarter.
&bull; Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $47.00 million.
&bull; Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is likely to report quarterly loss at $0.31 per share on revenue of $35.64 million.
&bull; PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $110.40 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACTG

ADBE

AGEN

AGRO

AKBA

ALAR

ALLO

ALTG

AMPS

AUTL

AVAH

Mobile Infrastructure Corporation Common Stock

BEEP

BEKE

BHIL

BKTI

BLND

BLNK

BRLT

CDLX

CION

CLPR

CNTY

CODX

CSIQ

CTSO

DESP

ETON

EVCM

EVOK

FEIM

FTHM

FUTU

GETY

GIII

GOCO

GURU

HFFG

HGBL

HSON

KNDI

KODK

KOPN

KPLT

LIFE

MCHX

MNTK

MOLN

MOMO

MOND

PHAR

PSQH

RGTI

RMBL

SCWX

SKLZ

SMAR

Spruce Power Holding Corporation Class A Common Stock

SPRU

STKS

TLYS

ULTA

URGN

VXRT

XNET

ZUMZ

Earnings Scheduled For March 14, 2024

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement.
Analysts estimate that InfuSystems Holdings will report an earnings per share (EPS) of $0.00. 
InfuSystems Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 5.46% drop in the share price the next day.
Here's a look at InfuSystems Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.02</td>
<td>0</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.03</td>
<td>0.02</td>
<td>-0.02</td>
<td>0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>5.0%</td>
<td>7.000000000000001%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710356482_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of InfuSystems Holdings were trading at $9.14 as of March 12. Over the last 52-week period, shares are up 34.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/INFU/earnings">To track all earnings releases for InfuSystems Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: InfuSystems Holdings

Every investor hopes to uncover a growth stock, an equity poised for rapid appreciation and substantial long-term returns. The real challenge lies ...

These 2 'Strong Buy' Medical Device Stocks Are Poised for Growth, Says Analyst

InfuSystem GAAP EPS of $0.08 beats by $0.02, revenue of $35.3M beats by $0.82M

Reports Q3 revenue $35.3M, consensus $34.48M. Q3 Richard DiIorio said, "Our Q3 financial results reflect the forecasted acceleration in our busines...

InfuSystem reports Q3 EPS 8c, consensus 6c

2023 revenue was $125.78M, consensus for 2024 revenue is $136.26M. Published first on TheFly – the ultimate source for real-time, market-moving bre...

InfuSystem still sees 2024 revenue growth in high-single-digits

InfuSystem Holdings, Inc. (INFU) Receives a Buy from Lake Street

InfuSystem Holdings, Inc. ( ($INFU) ) has released its Q3 earnings. Here is a breakdown of the information InfuSystem Holdings, Inc. presented to i...

InfuSystem Holdings Reports Strong Q3 2024 Earnings

InfuSystem Holdings, Inc. (INFU) Q3 2024 Earnings Call Transcript

InfuSystem Holdings, Inc. ( ($INFU) ) has provided an announcement. InfuSystem Holdings, Inc. has appointed Ron Hundzinski as an independent direct...

InfuSystem Holdings Appoints Ron Hundzinski as Director

Virtual Meeting to be held on November 20 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

InfuSystem management to meet virtually with B. Riley

InfuSystem Holdings, Inc. ( ($INFU) ) just unveiled an update. InfuSystem, a leading medical equipment provider, has achieved five consecutive year...

InfuSystem Achieves Five Years of Record Revenue Growth

TCMD

Press Releases

InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System and First Shipment of NPWT Systems

InfuSystem Reports Second Quarter 2024 Financial Results

InfuSystem to Participate in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference September 12, 2024

Sanara MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in, ChemoMouthpiece, LLC

InfuSystem and Sanara MedTech Inc. Announce Exclusive United States Distribution Agreement with ChemoMouthpiece, LLC

InfuSystem to Participate in Lytham Partners Fall 2024 Investor Conference on October 1, 2024

InfuSystem to Report Third Quarter 2024 Financial Results on November 7, 2024

InfuSystem Reports Third Quarter 2024 Financial Results

InfuSystem Appoints Ronald Hundzinski to the Board of Directors

InfuSystem to Present at Sidoti Small Cap Conference on December 4, 2024

SMTI

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

InfuSystems Holdings

Vendite allo scoperto

InfuSystems Holdings (AMEX:INFU) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO